N-Arenesulfonyl Amino Acids

Suflonamides are one of the most stable nitrogen protective groups, and a variety of these arenesulfonyl protecting groups are used in organic synthesis[1]. Traditionally, the tosyl group has been used for the protection of N_{α} amino function of amino acids in peptide synthesis[2]. At the same time, aryl sulfonyl groups are a major structural feature of a large number of bioactive compounds. Several groups of drugs are based on sulfonamides.

N-Sulfonyl amino acids are useful reagents for introducing the sulfonamide group in normal and combinatorial organic synthesis, especially in drug design. They are potent inhibitors of a number of enzymes, including HIV protease for the treatment of HIV[3], lens aldose reductase (cataract and retinopathy applications)[4], procollagen C-proteinase (treatment of inflammatory and fibrotic conditions)[5], NS3 protease of hepatitis C virus (antiviral activity)[6], etc.

Of special interest are sulfonamides containing bulky bicyclic aryl fragments (biphenyls and phenoxyphenyls). Compounds of this class have been widely used in the design of aggrecanase-1 inhibitors (treatment of osteoarthritis)[7], and a number of matrix metalloproteinase inhibitors (treatment of cancer, rheumatic and cardiovascular diseases)[8-10].

An extensive range of N-sulfonyl amino acids offered by Alfa Aesar is listed below.



H32698
1-(4′-Methoxy-4-biphenylylsulfonylamino) cyclohexanecarboxylic acid, 96%
[885269-48-7]



H32521
N-(4′-Methoxy-4-biphenylylsulfonyl)valine



H32299
N-(4′-Methoxy-4-biphenylylsulfonyl)glycine, 96%
[885269-46-5]



H31800
4-(2,3,5,6-Tetramethylphenylsulfonylamino) benzoic acid, 97%
[730249-87-3]



H32740
N-(2,3,5,6-Tetramethylphenylsulfonyl)glycine, 96%
[379250-94-9]



H32828
4-(4′-Methoxy-4-biphenylylsulfonylamino) benzoic acid, 96%
[885269-42-1]

N-Arenesulfonyl Amino Acids



H32750
N-(4′-Methoxy-4-biphenylylsulfonyl)leucine, 96%



H32855
N-(4′-Methoxy-4-biphenylylsulfonyl)-S-methylhomocysteine, 96%



H32511
N-(4′-Methoxy-4-biphenylylsulfonyl)-phenylalanine, 96%



H32459
N-(4′-Methoxy-4-biphenylylsulfonyl)-beta-alanine, 96%
[885269-51-2]



H31898
1-(2,3,5,6-Tetramethylphenylsulfonylamino) cyclohexanecarboxylic acid, 95%
[885269-54-5]



H32583
3-[4-(4-Methoxyphenyl)phenylsulfonamido] benzoic acid
[885269-91-0]



H34314
N-[4-(2-Methoxyphenoxy)phenylsulfonyl] phenylalanine, 96%
[1008961-78-1]



H34361
N-[4-(2-Methoxyphenoxy)phenylsulfonyl]-beta-alanine, 96%
[606944-94-9]



H33825
N-(2,5-Dimethylphenylsulfonyl)-beta-alanine, 96%
[568566-41-6]



H33889
N-(2,3,5,6-Tetramethylphenylsulfonyl) leucine, 96%



H33119
N-(2,3,5,6-Tetramethylphenylsulfonyl)-beta-alanine, 96%
[453581-60-7]



H32909
N-(2,3,5,6-Tetramethylphenylsulfonyl)valine monohydrate, 96%
[1009595-18-9]

N-Arenesulfonyl Amino Acids



H32312
N-(4′-Methoxy-4-biphenylylsulfonyl)alanine, 96%



H34230
N-[4-(2-Methoxyphenoxy)phenylsulfonyl] alanine, 96%
[1008052-20-7]



H31525
4-(2,3,5,6-Tetramethylphenylsulfonylamino-methyl)benzoic acid, 96%
[690646-18-5]



H33715
1-(2,5-Dimethylphenylsulfonylamino)-cyclohexanecarboxylic acid, 96%
[690646-16-3]



H32286
4-(4′-Methoxy-4-biphenylylsulfonylamino-methyl)benzoic acid, 96%
[885269-44-3]



H33819
1-(2,3,5,6-Tetramethylphenylsulfonyl) proline, 96%
[1009282-06-7]



H32890
1-(4′-Methoxy-4-biphenylylsulfonyl)proline, 96%

[1]Greene T.W., Wuts P.G.M. *Protective groups in organic synthesis, 3rd Ed.* John Wiley & Sons, N.Y., 1998, p. 603-616.
[2]Sewald N., Jakubke H.-D. *Peptides: chemistry and biology.* Wiley-VCH, Weinheim, 2002, p. 152-153.
[3]Stranix B.R., Sauve G., Bouzide A., Cote A., Sevigny G., Yelle J. Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the N_{α}-acyl-phenyl spacer. *Bioorg. Med. Chem. Lett.* 2003, V. 13, p. 4289-4292.
[4]DeRuiter J., Borne R.F., Mayfield C.A. N- and 2-substituted N-(phenylsulfony1)glycines as inhibitors of rat lens aldose reductase. *J . Med. Chem.* 1989, V. 32, p. 145-151.
[5]Dankwardt S.M., Martin R.L., Chan C.S., Van Wart H.E., Walker K.A.M., Delaet N.G., Robinson L.A. Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues. *Bioorg. Med. Chem. Lett.* 2001, V. 11, p. 2085-2088.
[6]Rönn R., Sabnis Y.A., Gossas T., Åkerblom E., Danielson U.H., Hallberg A., Johansson A. Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. *Bioorg. Med. Chem.* 2006, V. 14, p. 544-559.
[7]Hopper D.W., Vera M.D., How D., Sabatini J., Xiang J.S., Ipek M., Thomason J., Hu Y., Feyfant E., Wang Q., Georgiadis K.E., Reifenberg E., Sheldon R.T., Keohan C.C., Majumdar M.K., Morris E.A., Skotnicki J., Sum P.-E. Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: A class of potent aggrecanase-1 inhibitors. *Bioorg. Med. Chem. Lett.* 2009, V. 19, p. 2487-2491.
[8]O'Brien P.M., Ortwine D.F., Pavlovsky A.G., Picard J.A., Sliskovic D.R., Roth B.D., Dyer R.D., Johnson L.L., Man C.F., Hallak H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. *J. Med. Chem.* 2000, V. 43, p. 156-166.
[9]Whittaker M., Ayscough A. Matrix metalloproteinases and their inhibitors – current status and future challenges. *Celltransmissions* 2001, V. 17, p. 3-14.
[10]Fisher J.F., Mobashery S. Recent advances in MMP inhibitor design. *Cancer Metastasis* Rev. 2006, V. 25, p. 115-136.